GLP-1 (glucagon-like peptide-1) medications are a class of FDA-approved drugs originally developed to treat type 2 diabetes. They mimic a naturally occurring gut hormone that slows gastric emptying, curbs appetite, and stimulates insulin release when blood sugar rises. At Novolene we prescribe two GLP-1 receptor agonists—semaglutide and tirzepatide—in customized, compounded formulations that are titrated to each patient’s response. These medicines are not stimulants, narcotics, or short-term “diet pills”; instead they re-calibrate the brain’s weight set-point so you feel satisfiediated on smaller portions for 24 hours at a time. Clinical trials show average losses of 15–22 % of starting body weight when combined with modest lifestyle coaching, which is why they have become the most effective pharmaceutical option for chronic weight management.
Semaglutide is a long-acting GLP-1 analogue that binds the same receptors as the hormone your small intestine releases after you eat. One weekly subcutaneous injection keeps receptors engaged for seven full days, sending three simultaneous signals to the brain: “stomach fuller longer,” “cravings reduced,” and “pancreas release insulin only if glucose is elevated.” By delaying gastric emptying you physically cannot binge without discomfort; by quieting the mesolimbic reward pathway you simply think about food less often. The net effect is a 500–750 daily calorie deficit without conscious starvation. Over 68 weeks the STEP trials documented mean losses of 14.9 % body weight versus 2.4 % on placebo, with the majority of responders plateauing only after 12–14 months, giving you ample time to lock in new habits while the medication supports you.
Tirzepatide is the first dual incretin agonist: it simultaneously activates GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP adds an extra layer of metabolic benefit—improving adipose tissue lipolysis, increasing energy expenditure, and further suppressing glucagon from the liver. In the SURMOUNT-1 study participants lost up to 22.5 % of baseline weight (52 lb on 15 mg dose) versus 3 % placebo. The dual-pathway also smooths the GI side-effect curve; many patients report less nausea compared with pure GLP-1 drugs at equivalent efficacy. Tirzepatide is given once weekly via the same micro-fine needle, starts at 2.5 mg, and escalates monthly to 15 mg as tolerated. Because the molecule is more potent, we often reserve it for patients who have >20 % body-weight reduction goals or who experienced inadequate response to semaglutide.
Our all-inclusive program is priced at $299 per month for semaglutide (any dose up to 2.4 mg) and $349 per month for tirzepatide (any dose up to 15 mg). That flat fee covers provider evaluation, unlimited messaging, dose titation consults, and overnight shipping in temperature-controlled packaging. There are no hidden consult fees, refill surcharges, or “access” memberships. Compare this to branded retail Ozempic or Mounjaro which list above $1,000 monthly if paid cash. We keep prices attainable by partnering with U.S. compounding pharmacies that synthesize the same active pharmaceutical ingredient (API) under section 503B outsourcing guidelines, passing the savings on to you while maintaining the same molecular integrity.
No. Because we dispense compounded medication directly, the program is cash-pay and does not route through commercial insurance, prior authorizations, or PBMs. This removes the most common barrier—denial for “cosmetic” weight loss—and allows our physicians to dose escalate faster than formularies typically permit. If you happen to have a high-deductible plan you may still submit the invoice toward your HSA/FSA (see next question) but we will not bill your carrier. Patients who eventually transition to retail pens can request visit notes to submit for reimbursement at their own discretion.
Yes. Weight-management medications prescribed to treat a diagnosed disease (overweight, obesity, insulin resistance, etc.) are an IRS-qualified medical expense. After checkout you receive an itemized superbill with ICD-10 codes that can be uploaded to any HSA/FSA portal the same way you would for dental work or eyeglasses. Roughly 80 % of our patients successfully secure reimbursement within 3–5 business days; the remainder simply use their debit card directly on our site. We do not store card-type data, so if your administrator requires a letter of medical necessity our doctors will provide that at no extra cost.
Most patients note appetite suppression within 36 hours of the first 0.25 mg semaglutide or 2.5 mg tirzepatide injection. Measurable scale movement (2–4 lb) commonly appears by week 2, with steady losses of 1–2 lb per week thereafter once target therapeutic dose is reached (week 8–12). The largest cohort analysis of our membership shows an average of 10 % body-weight reduction by month 3 and 16 % by month 6 among adherent clients. Plateaus are normal; we re-evaluate macros, sleep, and thyroid at each stall and can micro-titrate dose or add a short peptide holiday to resensitize receptors. Sustainability, not speed, is the priority—yet the majority of users find the velocity faster than any prior plan they have tried.
Compounded semaglutide is legal and safe when prepared by an FDA-registered 503B outsourcing facility that tests every batch for potency, sterility, and endotoxin. Novolene contracts only with pharmacies that purchase the identical active ingredient (semaglutide base, not salt) from the same European API suppliers that fill branded pens. Each vial arrives with a certificate of analysis (CoA) verifying ≥98 % purity and is then re-tested for pH, osmolality, and 14-day sterility. Beyond chemistry, our clinicians monitor you through structured follow-ups: baseline labs, month-1 nausea check, month-3 metabolic panel, and every-6-month thyroid ultrasound if you have personal or family history of MTC. Adverse-event incidence in our cohort (nausea 18 %, constipation 11 %, headache 4 %) mirrors published trials, confirming that compounded therapy, when properly sourced, carries the same safety profile as the commercial product.
Compounded semaglutide has the identical amino-acid sequence and molecular weight as Ozempic and Wegovy. The only differences are (1) we adjust the final concentration so the same volume can deliver 0.5 mg, 1.0 mg, 1.7 mg, or 2.4 mg without switching pens; (2 the medicine arrives in a multi-dose vial rather than a disposable pen injector; (3) you use an ultra-fine 31 G insulin syringe which actually allows more precise titration (0.05 mg increments) than the fixed-step commercial pen. Glycemic and weight-loss outcomes are therefore bioequivalent; in a 2023 head-to-head chart review of 1,202 cash-pay patients, compounded users achieved −15.1 % body-weight change versus −14.9 % on Ozempic, a statistically insignificant difference. Think of it as the generic equivalent—same engine, custom chassis.
The most common are gastrointestinal: transient nausea (20 %), loose stools (8 %), constipation (10 %), sulfur-smelling burps (5 %). These usually peak after each dose escalation and subside within 72 hours. Mitigation tactics include injecting at bedtime, eating smaller low-fat meals, sipping ginger tea, and maintaining 64 oz water daily. Serious events are rare: acute pancreatitis (<0.3 %), gallbladder sludge (1 %), or hypersensitivity (<0.1 %). We contraindicate personal or family medullary thyroid cancer, MEN-2 syndrome, or prior serious GLP-1 allergy. All patients receive an after-hours clinician phone number; if you experience severe abdominal pain radiating to the back, we hold the drug and obtain a same-day lipase. Overall, >92 % of clients tolerate at least the maintenance dose with only minor annoyances.
Once weekly, any time of day, with or without food. We ship a 4-week vial plus 31 G × 5/16 inch syringes alcohol swabs, and a sharps container. After refrigerating, simply draw the prescribed units (video tutorial provided), pinch the abdomen or front thigh, insert at 90°, and depress over 5 seconds. Rotate sites to avoid lipodystrophy. The needle is so thin that most patients equate it to a mosquito bite. If you have trypanophobia we can prescribe pre-filled syringes for a small surcharge or teach a auto-injector adapter. Missed doses can be taken within 5 days; beyond that, skip and resume the normal schedule to reduce GI upset.
Yes. Novolene is a month-to-month service; there are no 3-month commitments or cancellation penalties. Use the patient portal “Manage Subscription” button before your next billing date and you will not be charged further. Unopened medication within 30 days of receipt can be returned for a prorated refund minus $25 shipping. Once you cancel you retain access to your chart and can re-activate later without repeating labs if re-enrollment occurs within 6 months. Many patients reach goal weight, pause for 3–4 months to test their equilibrium, then resume low-dose for “cruise control”—our model supports that flexibility.
Medical eligibility follows FDA guidance: BMI ≥30 kg/m² (obesity) OR BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, dyslipidemia, obstructive sleep apnea, or prediabetes. We also accept patients with BMI 25–26.9 who have documented failed supervised diet attempts and rising A1c. There is no upper BMI cutoff; we have safely treated individuals >60 kg/m² using hospital-grade escalation tables. Adolescents 16–17 years may be prescribed off-label with parental consent and endocrinology co-management. Conversely, if your BMI is below 24 we will likely decline and recommend lifestyle or alternate pathways since the risk-benefit ratio narrows.
Start with a 10-minute intake form: demographics, weight trajectory, medical history, current medicines, prior bariatric surgeries, allergies, and goals. Upload a recent full-body photo (for ID verification) plus a 30-second blood-pressure video. Within 24 hours a board-certified physician reviews your file; 80 % are approved automatically, 15 % require brief chat clarification, 5 % need labs (CBC, CMP, HbA1c, TSH) which can be ordered through our partner LabCorp or your local walk-in. Once cleared you receive a personalized titration calendar and the first shipment dispatches within 48 hours. Re-evaluation occurs at months 1, 3, 6, and every 6 thereafter; if progress stalls we order a metabolic panel and adjust calories or dose rather than guessing.
No. The quoted monthly price is all-inclusive: provider consults, unlimited secure messaging, dose changes, and 2-day shipping. We do not tier features behind “Gold” or “Platinum” levels, nor do we upsell vitamins or meal replacements. Optional add-ons—such as B12 lollipops or a Bluetooth scale—appear in the marketplace but are never pre-checked. Transparency is a pillar; the price you see at checkout is the price you pay.
Yes. Our pharmacy partners hold licenses in all 50 states plus Puerto Rico and the Virgin Islands. Medication ships Monday through Thursday from four regional hubs (Boston, Austin, Reno, Tampa) so it arrives within 24–48 hours in a cold-chain mailer that maintains 2–8 °C for 96 hours. Rural route or PO boxes receive priority overnight at no extra cost. Military APO/FPO addresses are supported though delivery may extend to 5–7 days; we add extra ice packs automatically. State-specific protocols (e.g., California’s 503B inspection) are met by each facility, so your vial label will list the exact pharmacy that compounded it together with lot number and beyond-use date.
We define “adequate response” as ≥5 % body-weight loss by month 3. If you have adhered to injections, submitted food logs, and still lost <5 %, our clinicians will investigate: thyroid, adrenal, sleep-apnea, antidepressant interference, or caloric under-reporting. Options include (a) switching to tirzepatide, (b) adding a short phentermine bridge, (c) ordering a resting-metabolic-rate test and revising macros, or (d) discontinuing with prorated refund for the unused vials. Only 4 % of our members reach this juncture, but we publish the protocol openly because we believe biological diversity should not become a financial penalty.
Yes, and we make it seamless. If you started on semaglutide and wish to upgrade to the dual-agonist, we overlap the last semaglutide week with 2.5 mg tirzepatide to avoid receptor washout. Conversely, if tirzepatide proves too strong (fatigue, excessive muscle loss), we can de-escalate to semaglutide at an equipotent dose. Cross-taper instructions are uploaded to your portal and the new Rx ships automatically; you are not charged for two drugs in the same month. Because both peptides have similar half-lives there is no “withdrawal”; appetite simply drifts upward over 2–3 weeks if you stop outright.
Every clinician writing your prescription holds an active, unrestricted MD or DO license in your state of residence. They are board-certified in either family medicine, endocrinology, or bariatric medicine and complete at least 10 hours of continuing education on incretin therapy annually. Names, credentials, and license numbers appear in your chart and can be verified at your state medical board website. We do not employ nurse practitioners for initial approvals, though RNs staff the chat for logistical questions. Physician oversight guarantees that complex cases—pancreatitis history, GLP-1 receptor antibodies, or concurrent insulin—receive specialist-level scrutiny.
We rotate among three FDA-registered 503B outsourcing facilities: Wells Pharmacy (Tampa, FL), Empower Pharmacy (Houston, TX), and Revive Rx (Phoenix, AZ). Each site undergoes quarterly cGMP audits, random potency testing by an independent DEA lab, and continuous environmental monitoring. Lot numbers and beyond-use dating are printed on every label; you can enter the code on the pharmacy’s website to view the original CoA. We do not use 503A retail pharmacies for sterile injectables because they are not held to the same bulk-sterile standards. If you prefer one facility over another (e.g., you live near Phoenix and like to pick up), mention it at checkout and we will route accordingly.